Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

C9orf72-mediated neurodegeneration: mechanisms and therapeutics

C9ND

An expanded GGGGCC repeat in a non-coding region of the C9orf72 gene is the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The repeat RNA is transcribed and accumulates in neuronal RNA aggregates, implicating RNA toxicity as a key pathogenic mechanism. However, the pathways that lead to...

Funding Programme
Start Date
End Date
Total Funding
€ 1 985 699
European Countries Involved

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...

Funding Programme
Start Date
End Date
Total Funding
€ 3 657 195

Characterising protein oligomers and their role in neurodegenerative disease in humans

Oligomers

Small soluble protein aggregates play a key role in the onset and spreading of Alzheimer’s and Parkinson’s diseases. However, which oligomers are present in human disease and which are toxic remains unknown because ultrasensitive methods do not exist to detect and characterise the low concentration of oligomers, which are highly heterogeneous in...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 551
European Countries Involved

Characterising protein oligomers and their role in neurodegenerative disease in humans

Oligomers

Small soluble protein aggregates play a key role in the onset and spreading of Alzheimer’s and Parkinson’s diseases. However, which oligomers are present in human disease and which are toxic remains unknown because ultrasensitive methods do not exist to detect and characterise the low concentration of oligomers, which are highly heterogeneous...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 551
European Countries Involved

CO-desiGning demeNtia dIagnoSis ANd post-diagnostic CarE

COGNISANCE

People with dementia and their care partners are often dissatisfied with the process of diagnosis, communication and recommendations after diagnosis. We aim to design with people with dementia, their care partners and clinicians recommendations and campaigns for all concerned on how to improve diagnostic process and post-diagnostic care in Europe...

Funding Programme
Start Date
End Date
Total Funding
€ 1 500 000
European Countries Involved

Common mechanisms and pathways in Stroke and Alzheimer's disease.

CoSTREAM

Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists...

Funding Programme
Start Date
End Date
Total Funding
€ 5 100 373
European Countries Involved

COMORBIDITY MECHANISMS UTILIZED IN HEALTHCARE

COMMUTE

The COVID pandemic can be seen as an experiment done with the entirety of humankind (as almost everybody has been or will get infected with SARS-CoV-2). It will therefore have the best coverage over the widest variation possible and is therefore ideally suited to study the effects of infections with SARS-CoV-2 on large quantities of heterogeneous...

Funding Programme
Start Date
End Date
Total Funding
€ 7 280 986

COnfident DEcisions

CODE

Virtually every decision people make comes with a sense of confidence – a subjective estimate of decision quality. The human capacity for confidence has tremendous social, clinical, and industrial impact. For example, children who can correctly judge their own level of confidence perform better academically. In the elderly, confidence declines...

Funding Programme
Start Date
End Date
Total Funding
€ 2 446 322
European Countries Involved

Consortium on Health and Ageing: Network of Cohorts in Europe and the United States

CHANCES

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these...

Funding Programme
Start Date
End Date
Total Funding
€ 15 410 903

Control of cerebral blood flow by capillary pericytes in health and disease

BrainEnergy

Pericytes, located at intervals along capillaries, have recently been revealed as major controllers of brain blood flow. Normally, they dilate capillaries in response to neuronal activity, increasing local blood flow and energy supply. But in pathology they have a more sinister role. After artery block causes a stroke, the brain suffers from the...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 954
European Countries Involved

Coordination Action in support of the implementation of a Joint Programming Initiative for Combating Neurodegenerative Diseases, in particular Alzheimer’s disease

JUMPAHEAD

The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND). Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of...

Funding Programme
Start Date
End Date
Total Funding
€ 2 618 090

Critical solutions for elderly well-being

RISE-WELL

Mental health and emotional well-being during old age (60\) should be regarded as important as at any other time of a persons’ life. Older people are more likely to experience events that affect emotional well-being, such as bereavement or disability. Unfortunately, mental health problems are under identified in older people, whom themselves are...

Funding Programme
Start Date
End Date
Total Funding
€ 2 691 279
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).